MicroBioGen and Novonesis have expanded their 11-year bioethanol partnership into biochemicals amongst other products. Through the expanded partnership, the companies aim to deliver yeast innovations to the global bioethanol market.
MicroBioGen, an Australia-based yeast biotech company and provider of ‘Yeast Innovation as a Service’, has expanded its existing long-term global bioethanol partnership with biosolutions company Novonesis into biochemicals amongst other products. The expanded partnership aims to leverage MicroBioGen’s portfolio of yeast strains and Novonesis’ R&D and commercialization expertise to provide yeast innovations for the global bioethanol market.
Geoffrey Bell, MicroBioGen CEO and Co-Founder, commented: “MicroBioGen is thrilled to be expanding our partnership with Novonesis. Both organisations are committed to delivering innovative solutions, as demonstrated by our 11-year partnership in the bioethanol industry.”
“The expanded partnership demonstrates the extensive potential of our combined innovation. MicroBioGen’s platform of yeast chassis are redefining what can be achieved in both GM and Non-GM applications, from ‘drop-in’ products to emerging industries such as biochemicals. We look forward to extending our innovative solutions to new sectors and building on the success of our collaboration with Novonesis on Innova® yeast products in the bioethanol industry,” he added.
“At Novonesis, we are dedicated to delivering exceptional value to our customers by harnessing the power of cutting-edge yeast technology,” stated Katy Cagle, Head of Bioenergy Business Unit at Novonesis. “Our collaboration with MicroBioGen exemplifies our shared commitment to innovation and excellence, setting new industry standards through our Innova® platform. As we expand our partnership, we are focused on developing next-generation biosolutions that meet the industry’s future needs and create lasting impact.”
